The startup develops antidepressants and cognitive enhancers that improve brain plasticity and reduce neuroinflammation, targeting conditions such as dementia, depression, and Alzheimer's. By monitoring mental health and enhancing synaptic function, the company aims to prevent cognitive degradation in patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for neurological disorders like depression, Alzheimer's disease, PTSD and chronic pain often fail to fully address the underlying issues of cognitive decline and emotional instability. Existing pharmaceutical interventions may have limited efficacy in improving brain plasticity and reducing neuroinflammation, leaving patients with persistent symptoms.
Solution
Neurorive develops novel therapeutics designed to enhance brain plasticity and reduce neuroinflammation, targeting the root causes of various central nervous system disorders. Their approach focuses on improving synaptic function and promoting emotional and cognitive flexibility to restore a sense of well-being. By addressing the neurobiological mechanisms underlying conditions like depression, Alzheimer's disease, PTSD, and chronic pain, Neurorive aims to provide more effective and sustainable relief for patients. The company's research and development efforts are geared towards creating innovative treatments that can prevent cognitive degradation and improve overall mental health.
Target Audience
The primary target audience includes individuals suffering from depression, Alzheimer's disease, PTSD, chronic pain, and other neurological disorders, as well as healthcare providers specializing in these conditions.
Features
- Development of pharmaceutical interventions for depression, Alzheimer's disease, PTSD and chronic pain
- Focus on enhancing brain plasticity and reducing neuroinflammation
- Aims to improve synaptic function and promote emotional and cognitive flexibility